Immunome, Inc. (IMNM) has a negative trailing P/E of -8.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 16.9 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -11.22%, forward earnings yield 5.92%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -1.9 | 0.00 | -0.58 | 0.00 | - |
| 2019 | -7.3 | 0.10 | -2.17 | 0.00 | - |
| 2020 | -5.5 | 0.67 | 2.37 | 0.00 | - |
| 2021 | -6.1 | -0.23 | 3.10 | 0.00 | - |
| 2022 | -0.7 | -0.02 | 1.61 | 0.00 | - |
| 2023 | -2.0 | -0.03 | 1.77 | 15.15 | - |
| 2024 | -2.1 | 0.30 | 3.44 | 68.88 | - |
| 2025 | -8.8 | 0.17 | 2.96 | 270.32 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-7.18 | $0.00 | $-7.85M | - |
| 2019 | $-1.84 | $0.00 | $-10.55M | - |
| 2020 | $-1.69 | $0.00 | $-17.12M | - |
| 2021 | $-2.12 | $0.00 | $-24.47M | - |
| 2022 | $-3.09 | $0.00 | $-37.51M | - |
| 2023 | $-5.38 | $14.02M | $-106.81M | -761.9% |
| 2024 | $-5.00 | $9.04M | $-292.96M | -3240.4% |
| 2025 | $-2.43 | $6.94M | $-212.39M | -3060% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.41 | $-2.74 – $-2.01 | $4.44M | $2.05M – $6.82M | 11 |
| 2027 | $-2.22 | $-2.81 – $-1.64 | $82.24M | $12.81M – $169.08M | 9 |
| 2028 | $-1.18 | $-2.86 – $-0.48 | $240.3M | $36.06M – $558.78M | 8 |
| 2029 | $-0.06 | $-0.16 – $0.01 | $404.13M | $60.64M – $939.75M | 6 |
| 2030 | $1.36 | $-0.14 – $3.69 | $623.98M | $93.64M – $1.45B | 6 |
